Development of iron-chelating agents for clinical use [editorial; comment]

Development of iron-chelating agents for clinical use.

Iron chelating agents for treating malaria.

BACKGROUND Researchers are exploring the effects of adding treatments to the main antimalarial regimens in an attempt to reduce mortality from Plasmodium falciparum. Iron chelation is one potential chemotherapeutic adjuvant treatment. Before advocating adjunctive therapy, the effects of iron chelators in improving patient outcomes need to be examined. OBJECTIVES To assess the effects of iron-...

Synthetic chelating agents in iron metabolism.

Iron in man is held within the cells incorporated in organic complex molecules, either as functional iron, i.e., hemoglobin and tissue enzymes, or as storage iron, i.e., ferritin and hemosiderin. Owing to the requirements of the erythroid marrow in particular, large amounts of iron must constantly pass from one cell to another through the plasma. This plasma transport is brought about by a #3gl...

Using Iron-Chelating Agents in Critically Ill Patients with Iron Overload. Fact or Fiction?

Recently, some evidence has shown that the failure of iron homeostasis may occur in critically ill patients and can lead to iron overload. Elevated ferritin levels as a body iron burden index in critically ill patients may be associated with depressed level of consciousness and greater mortality. However, the necessity of using iron-chelating agents in clinical situation is still unknown for th...

Biological activities of pyochelins: iron-chelating agents of Pseudomonas aeruginosa.

Strains of Pseudomonas aeruginosa able to grow readily in serum (serum resistant) produce siderophores in large quantity, enabling them to extract iron from transferrins. The term pyochelin has been proposed for this group of compounds. Pyochelin extractable with ethyl acetate and designated pyochelin A appears to be a mixture of catechols and other phenolates. The structures of water-soluble s...